Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke Receives Positive FDA Feedback

Algernon Pharmaceuticals (CSE: AGN – OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to discuss the Company’s response from the FDA in regard to Algernon Pharmaceuticals investigating the use of DMT in the rehabilitation of stroke.

Mr. Moreau explains to Proactive how the FDA provided valuable input into the design of the Company’s planned Phase 1 clinical trial, which will be conducted through Hammersmith Medicines Research in the UK, in Q4-2021.